Hyperbaric oxygen therapy has long occupied an ambiguous position in medicine. Accepted without controversy for decompression sickness and carbon monoxide poisoning, it has remained stubbornly contested for everything else — celebrated in integrative medicine circles, dismissed by much of academic medicine, and caught in a regulatory grey zone that makes rigorous clinical research difficult to fund. That picture is changing, and the change is largely coming from one institution.
The Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center in Israel, directed by Professor Shai Efrati, has published a body of clinical research on HBOT for neurological conditions that is increasingly difficult for skeptics to dismiss. With over 30 published studies, randomized controlled trials in several neurological conditions, and a dataset of thousands of treated patients, the Sagol Center has done what no other institution has attempted at scale: treated HBOT for brain injury as a serious medical question worthy of rigorous scientific investigation.
The Neurological Mechanism: Why Oxygen Matters to the Brain
The brain is metabolically extraordinary — consuming approximately 20% of the body’s oxygen supply while comprising only 2% of its mass. Under normal atmospheric conditions, oxygen is delivered primarily via hemoglobin-bound transport. At hyperbaric pressure — typically 1.5 to 2.4 atmospheres absolute (ATA) in clinical protocols — oxygen dissolves directly into plasma, cerebrospinal fluid, and lymphatic fluid, achieving tissue concentrations up to 20 times higher than ambient breathing.
Professor Efrati’s group has identified what they term the “neuroplasticity trigger” — the hypothesis that cycles of elevated and normalized oxygen tension, rather than continuously elevated oxygen alone, induce the angiogenic and neurogenic responses responsible for HBOT’s neurological effects. This intermittent exposure model is mechanistically analogous to the exercise-induced hormetic stress that drives cardiovascular adaptation. The practical implication is that protocols matter: a standard 90-minute session at 2.0 ATA, five days per week for eight weeks (40 total sessions), has become the Sagol Center’s benchmark protocol for most neurological indications.
Traumatic Brain Injury: The Evidence Base
The most robust neurological evidence for HBOT concerns traumatic brain injury, both acute and chronic. A landmark randomized controlled trial published in PLOS ONE in 2013 by Efrati and colleagues examined 56 patients with persistent post-concussion syndrome — symptoms lasting more than three months following mild-to-moderate TBI — and compared 40 HBOT sessions to a crossover sham control. HBOT produced significant improvements in cognitive function (memory, attention, information processing speed), quality of life scores, and — critically — measurable changes on SPECT brain imaging consistent with restored perfusion in previously hypoperfused regions.
A 2022 study by the same group, published in PNAS, extended this work to veterans with chronic TBI and post-traumatic stress disorder. The randomized trial found that HBOT significantly outperformed sham on cognitive outcomes and that the effects were accompanied by changes in brain microstructure visible on diffusion tensor imaging (DTI) — an objective neuroimaging marker. This kind of imaging-correlated improvement is particularly important because it distinguishes genuine neurological change from placebo response.
The NFL has taken notice. Several current and former professional football players have undergone HBOT at facilities offering the Sagol protocol, and while anecdotal reports should be weighted accordingly, the biological plausibility of HBOT for sports-related concussive injury is now taken seriously by a meaningful fraction of sports medicine physicians.
Long COVID and Neurological Sequelae
Perhaps the most societally significant recent finding from the Sagol Center concerns post-COVID cognitive syndrome — the constellation of memory impairment, executive dysfunction, fatigue, and mood disturbance affecting an estimated 10-30% of COVID-19 survivors regardless of initial illness severity.
A randomized, sham-controlled, double-blind trial published in Nature Communications in 2022 (Gil et al.) examined 73 long COVID patients with objectively documented cognitive impairment. Forty sessions of HBOT (2.0 ATA, 90 minutes, five days per week) produced significant improvements in cognitive function, fatigue, sleep quality, and pain measures compared to sham. Brain perfusion imaging showed significant increases in regional cerebral blood flow in the frontal lobe and temporal lobe regions associated with the cognitive domains affected. Microstructural white matter changes on advanced MRI were also documented.
This is the kind of data that changes practice. Long COVID has posed a genuine therapeutic challenge — there is no approved pharmacological treatment, and symptomatic management yields limited results. The Sagol Center’s data suggests that HBOT may represent one of the few interventions with a genuine biological rationale and supporting clinical evidence.
Access and Cost: The Practical Reality
In Israel, HBOT at the Sagol Center is covered for certain indications by the national health system; the waiting list for non-covered indications runs several months. For international patients seeking treatment — and the center has become a destination for medical tourists specifically seeking neurological HBOT — the cost structure is approximately $7,000 to $12,000 for a 40-session protocol, depending on accommodation and program package.
In the United States, FDA approval of HBOT extends to 13 indications that do not include TBI, long COVID, or most neurological applications. This means that neurological HBOT in the U.S. is administered as an “off-label” service, typically not covered by insurance, and offered through a mix of hospital hyperbaric departments, standalone clinics, and a smaller number of integrative medicine practices. Pricing ranges from $150 to $350 per session at reputable clinical-grade facilities, making a 40-session protocol a $6,000 to $14,000 investment. Many patients seeking Sagol-protocol treatment elect to travel to Israel, where the institutional experience is unmatched.
What separates clinical-grade HBOT from the increasingly common “mild hyperbaric” chambers offered at wellness centers is pressure. The Sagol protocols operate at 2.0 ATA. “Soft chamber” units widely marketed for home use or offered in spa settings typically achieve 1.3 to 1.5 ATA — insufficient to dissolve meaningful amounts of oxygen into plasma and almost certainly insufficient to replicate the neurological effects documented in clinical research. This distinction is not semantic; it is the difference between a medical intervention and a pressurized relaxation chamber.
Who Is a Candidate?
The patient profile most likely to benefit from neurological HBOT is someone with documented cognitive impairment — not subjective “brain fog” alone, but objectively measured deficits on validated neuropsychological testing — following TBI or COVID infection, where symptoms have persisted for at least three months. The Sagol group’s research consistently shows that chronic rather than acute injuries respond to the protocol, likely because the neuroplasticity-triggering mechanism requires a brain that has stabilized past the acute inflammatory phase.
Contraindications include active ear or sinus infections (due to barotrauma risk), certain pulmonary conditions, and recent optic neuritis. Claustrophobia is a practical barrier for some patients in hard-sided monoplace chambers, though multiplace chambers (in which the patient sits in a pressurized room rather than a tube) typically resolve this concern.
The trajectory of this field suggests that within a decade, neurological HBOT will likely be an established standard of care for specific indications rather than an integrative outlier. The Sagol Center’s methodological rigor has created an evidence base that is increasingly challenging for regulatory agencies and insurance systems to ignore. For patients seeking neurological recovery today, however, the practical path requires navigating access barriers that the research has outpaced.
[ QUICK POLL // 60 SECONDS ]